0

Close
 
Upcoming Allied Market Research
2023
Organ Transplant Immunosuppressant Drugs Market

Organ Transplant Immunosuppressant Drugs Market

by THERAPEUTICS (Heart Transplant, Lung Transplant, Kidney Transplant, Liver Transplant) and by COMMERCIALIZED PRODUCTS (Zenapax, Prograf, Cellcept, Myfortic, Neoral): Global Opportunity Analysis and Industry Forecast, 2023-2032

LS : Diagnostics and Biotech
Report Code: A00237
Nov 2023 | Pages: NA
Tables: NA
Charts: NA

  • Formats*:

  • pdf

    Single User License, Five User
    License & Enterprise User License

  • xls

    Data Pack Excel License

  • ppt

    It comes with the additional cost
    of $2500.00 contact sales.
 

COVID-19

Pandemic disrupted the entire world and affected many industries.

Get detailed COVID-19 impact analysis on the Organ Transplant Immunosuppressant Drugs Market

Request Now !

Organ transplant immunosuppressant drugs are the category of drugs which are administered to minimize the chances of organ rejection after transplantation. When a person undergoes any transplantation, the body recognizes the transplant as a foreign tissue and attacks it, resulting in rejection. These drugs dilute the immune system, hence reducing the reaction towards the transplant. The factors driving this market include the advancements made in tissue engineering and organ transplantations. These transplantations help in survival of many patients as well as enhance the quality of life. The lack of availability of organs and high cost of transplantation are the limitations for the growth of this market. The increase in use of tissue engineering for generation of implants provides growth opportunity to this market.

GLOBAL ORGAN TRANSPLANT IMMUNOSUPPRESSANT DRUGS THERAPEUTICS MARKET ANALYSIS

On the basis of therapeutics, this market is classified into heart transplant, lung transplant, kidney transplant and liver transplant. Kidney transplant has a well established market although heart transplant is expected to have potential growth. 

ORGAN TRANSPLANT IMMUNOSUPPRESSANT DRUGS GEOGRAPHY MARKET ANALYSIS

On the basis of geography, this market is classified into North America, Europe, Asia-Pacific and rest of the world (RoW). Asia-Pacific region is expected to have greater share in this market in the coming years. This growth would be due to promotion of medical tourism in these countries.

COMPETITIVE LANDSCAPE

The major companies included in the report are AstellasPharma, Genzyme Corporation, Accord Healthcare Ltd., Watson Pharmaceuticals, Inc., Novartis AG, Mylan Laboratories, Inc., GlaxoSmithKline plc, and Hoffman La Roche. Key companies in the report are seeking for approval strategy for the commercialization of their pipeline drugs. Therefore, the companies are adopting approval and clearance as key developmental strategies. 

HIGH LEVEL ANALYSIS

Organ transplant immunosuppressant drugs market has accelerated the growth of rapid organ transplant by reducing the harmful side effects such as autoimmune diseases. These novel drug therapies are strategically analyzed in the report in order to provide comparative benefits. The report is also focusing on the regulatory issues and commercial mandate that are hindering the growth. Porter’s five forces model is strategically analyzed in the report to project current and future market scenarios. The value chain analysis of the organ transplant immunosuppressant drugs market is dealt strategically. Top wining strategies adopted by the key players competing in this market are critically analyzed through primaries.

KEY BENEFITS

  • Intelligence from key market segments through top investment pockets would help in providing strategic assistance to decision markers. 
  • Analysis of key market players and strategies adopted by them are dealt to give an insight on top contenders in the market
  • This report gives a detailed analysis of drivers and factors limiting market expansion of organ transplant immunosuppressant drugs 
  • Projections are made for the period by considering current market scenario and future potential
  • Porter’s five forces and SWOT analysis discussed would help in making strategic decisions

 Organ Transplant Immunosuppressant Drugs Market Report Highlights

Aspects Details
By THERAPEUTICS
  • Heart Transplant
  • Lung Transplant
  • Kidney Transplant
  • Liver Transplant
By COMMERCIALIZED PRODUCTS
  • Zenapax
  • Prograf
  • Cellcept
  • Myfortic
  • Neoral
By GEOGRAPHY
  • North America
  • Europe
  • Asia-Pacific
  • RoW
 

  • CHAPTER 1: INTRODUCTION

    • 1.1. Report Description

    • 1.2. Key Market Segments

    • 1.3. Key Benefits

    • 1.4. Research Methodology

      • 1.4.1. Primary Research

      • 1.4.2. Secondary Research

      • 1.4.3. Analyst Tools and Models

  • CHAPTER 2: EXECUTIVE SUMMARY

    • 2.1. CXO Perspective

  • CHAPTER 3: MARKET LANDSCAPE

    • 3.1. Market Definition and Scope

    • 3.2. Key Findings

      • 3.2.1. Top Investment Pockets

      • 3.2.2. Top Winning Strategies

    • 3.3. Porter's Five Forces Analysis

      • 3.3.1. Bargaining Power of Suppliers

      • 3.3.2. Threat of New Entrants

      • 3.3.3. Threat of Substitutes

      • 3.3.4. Competitive Rivalry

      • 3.3.5. Bargaining Power among Buyers

    • 3.5. Market Dynamics

      • 3.5.1. Drivers

      • 3.5.2. Restraints

      • 3.5.3. Opportunities

    • 3.6. COVID-19 Impact Analysis

  • CHAPTER 4: ORGAN TRANSPLANT IMMUNOSUPPRESSANT DRUGS MARKET, BY THERAPEUTICS

    • 4.1. Market Overview

      • 4.1.1 Market Size and Forecast, By Therapeutics

    • 4.2. Heart Transplant

      • 4.2.1. Key Market Trends, Growth Factors and Opportunities

      • 4.2.2. Market Size and Forecast, By Region

      • 4.2.3. Market Share Analysis, By Country

    • 4.3. Lung Transplant

      • 4.3.1. Key Market Trends, Growth Factors and Opportunities

      • 4.3.2. Market Size and Forecast, By Region

      • 4.3.3. Market Share Analysis, By Country

    • 4.4. Kidney Transplant

      • 4.4.1. Key Market Trends, Growth Factors and Opportunities

      • 4.4.2. Market Size and Forecast, By Region

      • 4.4.3. Market Share Analysis, By Country

    • 4.5. Liver Transplant

      • 4.5.1. Key Market Trends, Growth Factors and Opportunities

      • 4.5.2. Market Size and Forecast, By Region

      • 4.5.3. Market Share Analysis, By Country

  • CHAPTER 5: ORGAN TRANSPLANT IMMUNOSUPPRESSANT DRUGS MARKET, BY COMMERCIALIZED PRODUCTS

    • 5.1. Market Overview

      • 5.1.1 Market Size and Forecast, By Commercialized Products

    • 5.2. Zenapax

      • 5.2.1. Key Market Trends, Growth Factors and Opportunities

      • 5.2.2. Market Size and Forecast, By Region

      • 5.2.3. Market Share Analysis, By Country

    • 5.3. Prograf

      • 5.3.1. Key Market Trends, Growth Factors and Opportunities

      • 5.3.2. Market Size and Forecast, By Region

      • 5.3.3. Market Share Analysis, By Country

    • 5.4. Cellcept

      • 5.4.1. Key Market Trends, Growth Factors and Opportunities

      • 5.4.2. Market Size and Forecast, By Region

      • 5.4.3. Market Share Analysis, By Country

    • 5.5. Myfortic

      • 5.5.1. Key Market Trends, Growth Factors and Opportunities

      • 5.5.2. Market Size and Forecast, By Region

      • 5.5.3. Market Share Analysis, By Country

    • 5.6. Neoral

      • 5.6.1. Key Market Trends, Growth Factors and Opportunities

      • 5.6.2. Market Size and Forecast, By Region

      • 5.6.3. Market Share Analysis, By Country

  • CHAPTER 6: ORGAN TRANSPLANT IMMUNOSUPPRESSANT DRUGS MARKET, BY REGION

    • 6.1. Market Overview

      • 6.1.1 Market Size and Forecast, By Region

    • 6.2. North America

      • 6.2.1. Key Market Trends and Opportunities

      • 6.2.2. Market Size and Forecast, By Therapeutics

      • 6.2.3. Market Size and Forecast, By Commercialized Products

      • 6.2.4. Market Size and Forecast, By Country

      • 6.2.5. U.S. Organ Transplant Immunosuppressant Drugs Market

        • 6.2.5.1. Market Size and Forecast, By Therapeutics
        • 6.2.5.2. Market Size and Forecast, By Commercialized Products

      • 6.2.6. Canada Organ Transplant Immunosuppressant Drugs Market

        • 6.2.6.1. Market Size and Forecast, By Therapeutics
        • 6.2.6.2. Market Size and Forecast, By Commercialized Products

      • 6.2.7. Mexico Organ Transplant Immunosuppressant Drugs Market

        • 6.2.7.1. Market Size and Forecast, By Therapeutics
        • 6.2.7.2. Market Size and Forecast, By Commercialized Products

    • 6.3. Europe

      • 6.3.1. Key Market Trends and Opportunities

      • 6.3.2. Market Size and Forecast, By Therapeutics

      • 6.3.3. Market Size and Forecast, By Commercialized Products

      • 6.3.4. Market Size and Forecast, By Country

      • 6.3.5. France Organ Transplant Immunosuppressant Drugs Market

        • 6.3.5.1. Market Size and Forecast, By Therapeutics
        • 6.3.5.2. Market Size and Forecast, By Commercialized Products

      • 6.3.6. Germany Organ Transplant Immunosuppressant Drugs Market

        • 6.3.6.1. Market Size and Forecast, By Therapeutics
        • 6.3.6.2. Market Size and Forecast, By Commercialized Products

      • 6.3.7. Italy Organ Transplant Immunosuppressant Drugs Market

        • 6.3.7.1. Market Size and Forecast, By Therapeutics
        • 6.3.7.2. Market Size and Forecast, By Commercialized Products

      • 6.3.8. Spain Organ Transplant Immunosuppressant Drugs Market

        • 6.3.8.1. Market Size and Forecast, By Therapeutics
        • 6.3.8.2. Market Size and Forecast, By Commercialized Products

      • 6.3.9. UK Organ Transplant Immunosuppressant Drugs Market

        • 6.3.9.1. Market Size and Forecast, By Therapeutics
        • 6.3.9.2. Market Size and Forecast, By Commercialized Products

      • 6.3.10. Russia Organ Transplant Immunosuppressant Drugs Market

        • 6.3.10.1. Market Size and Forecast, By Therapeutics
        • 6.3.10.2. Market Size and Forecast, By Commercialized Products

      • 6.3.11. Rest Of Europe Organ Transplant Immunosuppressant Drugs Market

        • 6.3.11.1. Market Size and Forecast, By Therapeutics
        • 6.3.11.2. Market Size and Forecast, By Commercialized Products

    • 6.4. Asia-Pacific

      • 6.4.1. Key Market Trends and Opportunities

      • 6.4.2. Market Size and Forecast, By Therapeutics

      • 6.4.3. Market Size and Forecast, By Commercialized Products

      • 6.4.4. Market Size and Forecast, By Country

      • 6.4.5. China Organ Transplant Immunosuppressant Drugs Market

        • 6.4.5.1. Market Size and Forecast, By Therapeutics
        • 6.4.5.2. Market Size and Forecast, By Commercialized Products

      • 6.4.6. Japan Organ Transplant Immunosuppressant Drugs Market

        • 6.4.6.1. Market Size and Forecast, By Therapeutics
        • 6.4.6.2. Market Size and Forecast, By Commercialized Products

      • 6.4.7. India Organ Transplant Immunosuppressant Drugs Market

        • 6.4.7.1. Market Size and Forecast, By Therapeutics
        • 6.4.7.2. Market Size and Forecast, By Commercialized Products

      • 6.4.8. South Korea Organ Transplant Immunosuppressant Drugs Market

        • 6.4.8.1. Market Size and Forecast, By Therapeutics
        • 6.4.8.2. Market Size and Forecast, By Commercialized Products

      • 6.4.9. Australia Organ Transplant Immunosuppressant Drugs Market

        • 6.4.9.1. Market Size and Forecast, By Therapeutics
        • 6.4.9.2. Market Size and Forecast, By Commercialized Products

      • 6.4.10. Thailand Organ Transplant Immunosuppressant Drugs Market

        • 6.4.10.1. Market Size and Forecast, By Therapeutics
        • 6.4.10.2. Market Size and Forecast, By Commercialized Products

      • 6.4.11. Malaysia Organ Transplant Immunosuppressant Drugs Market

        • 6.4.11.1. Market Size and Forecast, By Therapeutics
        • 6.4.11.2. Market Size and Forecast, By Commercialized Products

      • 6.4.12. Indonesia Organ Transplant Immunosuppressant Drugs Market

        • 6.4.12.1. Market Size and Forecast, By Therapeutics
        • 6.4.12.2. Market Size and Forecast, By Commercialized Products

      • 6.4.13. Rest of Asia Pacific Organ Transplant Immunosuppressant Drugs Market

        • 6.4.13.1. Market Size and Forecast, By Therapeutics
        • 6.4.13.2. Market Size and Forecast, By Commercialized Products

    • 6.5. LAMEA

      • 6.5.1. Key Market Trends and Opportunities

      • 6.5.2. Market Size and Forecast, By Therapeutics

      • 6.5.3. Market Size and Forecast, By Commercialized Products

      • 6.5.4. Market Size and Forecast, By Country

      • 6.5.5. Brazil Organ Transplant Immunosuppressant Drugs Market

        • 6.5.5.1. Market Size and Forecast, By Therapeutics
        • 6.5.5.2. Market Size and Forecast, By Commercialized Products

      • 6.5.6. South Africa Organ Transplant Immunosuppressant Drugs Market

        • 6.5.6.1. Market Size and Forecast, By Therapeutics
        • 6.5.6.2. Market Size and Forecast, By Commercialized Products

      • 6.5.7. Saudi Arabia Organ Transplant Immunosuppressant Drugs Market

        • 6.5.7.1. Market Size and Forecast, By Therapeutics
        • 6.5.7.2. Market Size and Forecast, By Commercialized Products

      • 6.5.8. UAE Organ Transplant Immunosuppressant Drugs Market

        • 6.5.8.1. Market Size and Forecast, By Therapeutics
        • 6.5.8.2. Market Size and Forecast, By Commercialized Products

      • 6.5.9. Argentina Organ Transplant Immunosuppressant Drugs Market

        • 6.5.9.1. Market Size and Forecast, By Therapeutics
        • 6.5.9.2. Market Size and Forecast, By Commercialized Products

      • 6.5.10. Rest of LAMEA Organ Transplant Immunosuppressant Drugs Market

        • 6.5.10.1. Market Size and Forecast, By Therapeutics
        • 6.5.10.2. Market Size and Forecast, By Commercialized Products

  • CHAPTER 7: COMPETITIVE LANDSCAPE

    • 7.1. Introduction

    • 7.2. Top Winning Strategies

    • 7.3. Product Mapping Of Top 10 Player

    • 7.4. Competitive Dashboard

    • 7.5. Competitive Heatmap

    • 7.6. Top Player Positioning,2022

  • CHAPTER 8: COMPANY PROFILES

    • 8.1. Company 1

      • 8.1.1. Company Overview

      • 8.1.2. Key Executives

      • 8.1.3. Company Snapshot

      • 8.1.4. Operating Business Segments

      • 8.1.5. Product Portfolio

      • 8.1.6. Business Performance

      • 8.1.7. Key Strategic Moves and Developments

    • 8.2. Company 2

      • 8.2.1. Company Overview

      • 8.2.2. Key Executives

      • 8.2.3. Company Snapshot

      • 8.2.4. Operating Business Segments

      • 8.2.5. Product Portfolio

      • 8.2.6. Business Performance

      • 8.2.7. Key Strategic Moves and Developments

    • 8.3. Company 3

      • 8.3.1. Company Overview

      • 8.3.2. Key Executives

      • 8.3.3. Company Snapshot

      • 8.3.4. Operating Business Segments

      • 8.3.5. Product Portfolio

      • 8.3.6. Business Performance

      • 8.3.7. Key Strategic Moves and Developments

    • 8.4. Company 4

      • 8.4.1. Company Overview

      • 8.4.2. Key Executives

      • 8.4.3. Company Snapshot

      • 8.4.4. Operating Business Segments

      • 8.4.5. Product Portfolio

      • 8.4.6. Business Performance

      • 8.4.7. Key Strategic Moves and Developments

    • 8.5. Company 5

      • 8.5.1. Company Overview

      • 8.5.2. Key Executives

      • 8.5.3. Company Snapshot

      • 8.5.4. Operating Business Segments

      • 8.5.5. Product Portfolio

      • 8.5.6. Business Performance

      • 8.5.7. Key Strategic Moves and Developments

    • 8.6. Company 6

      • 8.6.1. Company Overview

      • 8.6.2. Key Executives

      • 8.6.3. Company Snapshot

      • 8.6.4. Operating Business Segments

      • 8.6.5. Product Portfolio

      • 8.6.6. Business Performance

      • 8.6.7. Key Strategic Moves and Developments

    • 8.7. Company 7

      • 8.7.1. Company Overview

      • 8.7.2. Key Executives

      • 8.7.3. Company Snapshot

      • 8.7.4. Operating Business Segments

      • 8.7.5. Product Portfolio

      • 8.7.6. Business Performance

      • 8.7.7. Key Strategic Moves and Developments

    • 8.8. Company 8

      • 8.8.1. Company Overview

      • 8.8.2. Key Executives

      • 8.8.3. Company Snapshot

      • 8.8.4. Operating Business Segments

      • 8.8.5. Product Portfolio

      • 8.8.6. Business Performance

      • 8.8.7. Key Strategic Moves and Developments

    • 8.9. Company 9

      • 8.9.1. Company Overview

      • 8.9.2. Key Executives

      • 8.9.3. Company Snapshot

      • 8.9.4. Operating Business Segments

      • 8.9.5. Product Portfolio

      • 8.9.6. Business Performance

      • 8.9.7. Key Strategic Moves and Developments

    • 8.10. Company 10

      • 8.10.1. Company Overview

      • 8.10.2. Key Executives

      • 8.10.3. Company Snapshot

      • 8.10.4. Operating Business Segments

      • 8.10.5. Product Portfolio

      • 8.10.6. Business Performance

      • 8.10.7. Key Strategic Moves and Developments

  • LIST OF TABLES

  • TABLE 1. GLOBAL ORGAN TRANSPLANT IMMUNOSUPPRESSANT DRUGS MARKET, BY THERAPEUTICS, 2022-2032 ($MILLION)
  • TABLE 2. GLOBAL ORGAN TRANSPLANT IMMUNOSUPPRESSANT DRUGS MARKET FOR HEART TRANSPLANT, BY REGION, 2022-2032 ($MILLION)
  • TABLE 3. GLOBAL ORGAN TRANSPLANT IMMUNOSUPPRESSANT DRUGS MARKET FOR LUNG TRANSPLANT, BY REGION, 2022-2032 ($MILLION)
  • TABLE 4. GLOBAL ORGAN TRANSPLANT IMMUNOSUPPRESSANT DRUGS MARKET FOR KIDNEY TRANSPLANT, BY REGION, 2022-2032 ($MILLION)
  • TABLE 5. GLOBAL ORGAN TRANSPLANT IMMUNOSUPPRESSANT DRUGS MARKET FOR LIVER TRANSPLANT, BY REGION, 2022-2032 ($MILLION)
  • TABLE 6. GLOBAL ORGAN TRANSPLANT IMMUNOSUPPRESSANT DRUGS MARKET, BY COMMERCIALIZED PRODUCTS, 2022-2032 ($MILLION)
  • TABLE 7. GLOBAL ORGAN TRANSPLANT IMMUNOSUPPRESSANT DRUGS MARKET FOR ZENAPAX, BY REGION, 2022-2032 ($MILLION)
  • TABLE 8. GLOBAL ORGAN TRANSPLANT IMMUNOSUPPRESSANT DRUGS MARKET FOR PROGRAF, BY REGION, 2022-2032 ($MILLION)
  • TABLE 9. GLOBAL ORGAN TRANSPLANT IMMUNOSUPPRESSANT DRUGS MARKET FOR CELLCEPT, BY REGION, 2022-2032 ($MILLION)
  • TABLE 10. GLOBAL ORGAN TRANSPLANT IMMUNOSUPPRESSANT DRUGS MARKET FOR MYFORTIC, BY REGION, 2022-2032 ($MILLION)
  • TABLE 11. GLOBAL ORGAN TRANSPLANT IMMUNOSUPPRESSANT DRUGS MARKET FOR NEORAL, BY REGION, 2022-2032 ($MILLION)
  • TABLE 12. GLOBAL ORGAN TRANSPLANT IMMUNOSUPPRESSANT DRUGS MARKET, BY REGION, 2022-2032 ($MILLION)
  • TABLE 13. NORTH AMERICA ORGAN TRANSPLANT IMMUNOSUPPRESSANT DRUGS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 14. NORTH AMERICA ORGAN TRANSPLANT IMMUNOSUPPRESSANT DRUGS, BY THERAPEUTICS, 2022-2032 ($MILLION)
  • TABLE 15. NORTH AMERICA ORGAN TRANSPLANT IMMUNOSUPPRESSANT DRUGS, BY COMMERCIALIZED PRODUCTS, 2022-2032 ($MILLION)
  • TABLE 16. U.S. ORGAN TRANSPLANT IMMUNOSUPPRESSANT DRUGS, BY THERAPEUTICS, 2022-2032 ($MILLION)
  • TABLE 17. U.S. ORGAN TRANSPLANT IMMUNOSUPPRESSANT DRUGS, BY COMMERCIALIZED PRODUCTS, 2022-2032 ($MILLION)
  • TABLE 18. CANADA ORGAN TRANSPLANT IMMUNOSUPPRESSANT DRUGS, BY THERAPEUTICS, 2022-2032 ($MILLION)
  • TABLE 19. CANADA ORGAN TRANSPLANT IMMUNOSUPPRESSANT DRUGS, BY COMMERCIALIZED PRODUCTS, 2022-2032 ($MILLION)
  • TABLE 20. MEXICO ORGAN TRANSPLANT IMMUNOSUPPRESSANT DRUGS, BY THERAPEUTICS, 2022-2032 ($MILLION)
  • TABLE 21. MEXICO ORGAN TRANSPLANT IMMUNOSUPPRESSANT DRUGS, BY COMMERCIALIZED PRODUCTS, 2022-2032 ($MILLION)
  • TABLE 22. EUROPE ORGAN TRANSPLANT IMMUNOSUPPRESSANT DRUGS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 23. EUROPE ORGAN TRANSPLANT IMMUNOSUPPRESSANT DRUGS, BY THERAPEUTICS, 2022-2032 ($MILLION)
  • TABLE 24. EUROPE ORGAN TRANSPLANT IMMUNOSUPPRESSANT DRUGS, BY COMMERCIALIZED PRODUCTS, 2022-2032 ($MILLION)
  • TABLE 25. FRANCE ORGAN TRANSPLANT IMMUNOSUPPRESSANT DRUGS, BY THERAPEUTICS, 2022-2032 ($MILLION)
  • TABLE 26. FRANCE ORGAN TRANSPLANT IMMUNOSUPPRESSANT DRUGS, BY COMMERCIALIZED PRODUCTS, 2022-2032 ($MILLION)
  • TABLE 27. GERMANY ORGAN TRANSPLANT IMMUNOSUPPRESSANT DRUGS, BY THERAPEUTICS, 2022-2032 ($MILLION)
  • TABLE 28. GERMANY ORGAN TRANSPLANT IMMUNOSUPPRESSANT DRUGS, BY COMMERCIALIZED PRODUCTS, 2022-2032 ($MILLION)
  • TABLE 29. ITALY ORGAN TRANSPLANT IMMUNOSUPPRESSANT DRUGS, BY THERAPEUTICS, 2022-2032 ($MILLION)
  • TABLE 30. ITALY ORGAN TRANSPLANT IMMUNOSUPPRESSANT DRUGS, BY COMMERCIALIZED PRODUCTS, 2022-2032 ($MILLION)
  • TABLE 31. SPAIN ORGAN TRANSPLANT IMMUNOSUPPRESSANT DRUGS, BY THERAPEUTICS, 2022-2032 ($MILLION)
  • TABLE 32. SPAIN ORGAN TRANSPLANT IMMUNOSUPPRESSANT DRUGS, BY COMMERCIALIZED PRODUCTS, 2022-2032 ($MILLION)
  • TABLE 33. UK ORGAN TRANSPLANT IMMUNOSUPPRESSANT DRUGS, BY THERAPEUTICS, 2022-2032 ($MILLION)
  • TABLE 34. UK ORGAN TRANSPLANT IMMUNOSUPPRESSANT DRUGS, BY COMMERCIALIZED PRODUCTS, 2022-2032 ($MILLION)
  • TABLE 35. RUSSIA ORGAN TRANSPLANT IMMUNOSUPPRESSANT DRUGS, BY THERAPEUTICS, 2022-2032 ($MILLION)
  • TABLE 36. RUSSIA ORGAN TRANSPLANT IMMUNOSUPPRESSANT DRUGS, BY COMMERCIALIZED PRODUCTS, 2022-2032 ($MILLION)
  • TABLE 37. REST OF EUROPE ORGAN TRANSPLANT IMMUNOSUPPRESSANT DRUGS, BY THERAPEUTICS, 2022-2032 ($MILLION)
  • TABLE 38. REST OF EUROPE ORGAN TRANSPLANT IMMUNOSUPPRESSANT DRUGS, BY COMMERCIALIZED PRODUCTS, 2022-2032 ($MILLION)
  • TABLE 39. ASIA-PACIFIC ORGAN TRANSPLANT IMMUNOSUPPRESSANT DRUGS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 40. ASIA-PACIFIC ORGAN TRANSPLANT IMMUNOSUPPRESSANT DRUGS, BY THERAPEUTICS, 2022-2032 ($MILLION)
  • TABLE 41. ASIA-PACIFIC ORGAN TRANSPLANT IMMUNOSUPPRESSANT DRUGS, BY COMMERCIALIZED PRODUCTS, 2022-2032 ($MILLION)
  • TABLE 42. CHINA ORGAN TRANSPLANT IMMUNOSUPPRESSANT DRUGS, BY THERAPEUTICS, 2022-2032 ($MILLION)
  • TABLE 43. CHINA ORGAN TRANSPLANT IMMUNOSUPPRESSANT DRUGS, BY COMMERCIALIZED PRODUCTS, 2022-2032 ($MILLION)
  • TABLE 44. JAPAN ORGAN TRANSPLANT IMMUNOSUPPRESSANT DRUGS, BY THERAPEUTICS, 2022-2032 ($MILLION)
  • TABLE 45. JAPAN ORGAN TRANSPLANT IMMUNOSUPPRESSANT DRUGS, BY COMMERCIALIZED PRODUCTS, 2022-2032 ($MILLION)
  • TABLE 46. INDIA ORGAN TRANSPLANT IMMUNOSUPPRESSANT DRUGS, BY THERAPEUTICS, 2022-2032 ($MILLION)
  • TABLE 47. INDIA ORGAN TRANSPLANT IMMUNOSUPPRESSANT DRUGS, BY COMMERCIALIZED PRODUCTS, 2022-2032 ($MILLION)
  • TABLE 48. SOUTH KOREA ORGAN TRANSPLANT IMMUNOSUPPRESSANT DRUGS, BY THERAPEUTICS, 2022-2032 ($MILLION)
  • TABLE 49. SOUTH KOREA ORGAN TRANSPLANT IMMUNOSUPPRESSANT DRUGS, BY COMMERCIALIZED PRODUCTS, 2022-2032 ($MILLION)
  • TABLE 50. AUSTRALIA ORGAN TRANSPLANT IMMUNOSUPPRESSANT DRUGS, BY THERAPEUTICS, 2022-2032 ($MILLION)
  • TABLE 51. AUSTRALIA ORGAN TRANSPLANT IMMUNOSUPPRESSANT DRUGS, BY COMMERCIALIZED PRODUCTS, 2022-2032 ($MILLION)
  • TABLE 52. THAILAND ORGAN TRANSPLANT IMMUNOSUPPRESSANT DRUGS, BY THERAPEUTICS, 2022-2032 ($MILLION)
  • TABLE 53. THAILAND ORGAN TRANSPLANT IMMUNOSUPPRESSANT DRUGS, BY COMMERCIALIZED PRODUCTS, 2022-2032 ($MILLION)
  • TABLE 54. MALAYSIA ORGAN TRANSPLANT IMMUNOSUPPRESSANT DRUGS, BY THERAPEUTICS, 2022-2032 ($MILLION)
  • TABLE 55. MALAYSIA ORGAN TRANSPLANT IMMUNOSUPPRESSANT DRUGS, BY COMMERCIALIZED PRODUCTS, 2022-2032 ($MILLION)
  • TABLE 56. INDONESIA ORGAN TRANSPLANT IMMUNOSUPPRESSANT DRUGS, BY THERAPEUTICS, 2022-2032 ($MILLION)
  • TABLE 57. INDONESIA ORGAN TRANSPLANT IMMUNOSUPPRESSANT DRUGS, BY COMMERCIALIZED PRODUCTS, 2022-2032 ($MILLION)
  • TABLE 58. REST OF ASIA PACIFIC ORGAN TRANSPLANT IMMUNOSUPPRESSANT DRUGS, BY THERAPEUTICS, 2022-2032 ($MILLION)
  • TABLE 59. REST OF ASIA PACIFIC ORGAN TRANSPLANT IMMUNOSUPPRESSANT DRUGS, BY COMMERCIALIZED PRODUCTS, 2022-2032 ($MILLION)
  • TABLE 60. LAMEA ORGAN TRANSPLANT IMMUNOSUPPRESSANT DRUGS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 61. LAMEA ORGAN TRANSPLANT IMMUNOSUPPRESSANT DRUGS, BY THERAPEUTICS, 2022-2032 ($MILLION)
  • TABLE 62. LAMEA ORGAN TRANSPLANT IMMUNOSUPPRESSANT DRUGS, BY COMMERCIALIZED PRODUCTS, 2022-2032 ($MILLION)
  • TABLE 63. BRAZIL ORGAN TRANSPLANT IMMUNOSUPPRESSANT DRUGS, BY THERAPEUTICS, 2022-2032 ($MILLION)
  • TABLE 64. BRAZIL ORGAN TRANSPLANT IMMUNOSUPPRESSANT DRUGS, BY COMMERCIALIZED PRODUCTS, 2022-2032 ($MILLION)
  • TABLE 65. SOUTH AFRICA ORGAN TRANSPLANT IMMUNOSUPPRESSANT DRUGS, BY THERAPEUTICS, 2022-2032 ($MILLION)
  • TABLE 66. SOUTH AFRICA ORGAN TRANSPLANT IMMUNOSUPPRESSANT DRUGS, BY COMMERCIALIZED PRODUCTS, 2022-2032 ($MILLION)
  • TABLE 67. SAUDI ARABIA ORGAN TRANSPLANT IMMUNOSUPPRESSANT DRUGS, BY THERAPEUTICS, 2022-2032 ($MILLION)
  • TABLE 68. SAUDI ARABIA ORGAN TRANSPLANT IMMUNOSUPPRESSANT DRUGS, BY COMMERCIALIZED PRODUCTS, 2022-2032 ($MILLION)
  • TABLE 69. UAE ORGAN TRANSPLANT IMMUNOSUPPRESSANT DRUGS, BY THERAPEUTICS, 2022-2032 ($MILLION)
  • TABLE 70. UAE ORGAN TRANSPLANT IMMUNOSUPPRESSANT DRUGS, BY COMMERCIALIZED PRODUCTS, 2022-2032 ($MILLION)
  • TABLE 71. ARGENTINA ORGAN TRANSPLANT IMMUNOSUPPRESSANT DRUGS, BY THERAPEUTICS, 2022-2032 ($MILLION)
  • TABLE 72. ARGENTINA ORGAN TRANSPLANT IMMUNOSUPPRESSANT DRUGS, BY COMMERCIALIZED PRODUCTS, 2022-2032 ($MILLION)
  • TABLE 73. REST OF LAMEA ORGAN TRANSPLANT IMMUNOSUPPRESSANT DRUGS, BY THERAPEUTICS, 2022-2032 ($MILLION)
  • TABLE 74. REST OF LAMEA ORGAN TRANSPLANT IMMUNOSUPPRESSANT DRUGS, BY COMMERCIALIZED PRODUCTS, 2022-2032 ($MILLION)
  • TABLE 75. COMPANY 1: KEY EXECUTIVES
  • TABLE 76. COMPANY 1: COMPANY SNAPSHOT
  • TABLE 77. COMPANY 1: OPERATING SEGMENTS
  • TABLE 78. COMPANY 1: PRODUCT PORTFOLIO
  • TABLE 79. COMPANY 1: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 80. COMPANY 2: KEY EXECUTIVES
  • TABLE 81. COMPANY 2: COMPANY SNAPSHOT
  • TABLE 82. COMPANY 2: OPERATING SEGMENTS
  • TABLE 83. COMPANY 2: PRODUCT PORTFOLIO
  • TABLE 84. COMPANY 2: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 85. COMPANY 3: KEY EXECUTIVES
  • TABLE 86. COMPANY 3: COMPANY SNAPSHOT
  • TABLE 87. COMPANY 3: OPERATING SEGMENTS
  • TABLE 88. COMPANY 3: PRODUCT PORTFOLIO
  • TABLE 89. COMPANY 3: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 90. COMPANY 4: KEY EXECUTIVES
  • TABLE 91. COMPANY 4: COMPANY SNAPSHOT
  • TABLE 92. COMPANY 4: OPERATING SEGMENTS
  • TABLE 93. COMPANY 4: PRODUCT PORTFOLIO
  • TABLE 94. COMPANY 4: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 95. COMPANY 5: KEY EXECUTIVES
  • TABLE 96. COMPANY 5: COMPANY SNAPSHOT
  • TABLE 97. COMPANY 5: OPERATING SEGMENTS
  • TABLE 98. COMPANY 5: PRODUCT PORTFOLIO
  • TABLE 99. COMPANY 5: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 100. COMPANY 6: KEY EXECUTIVES
  • TABLE 101. COMPANY 6: COMPANY SNAPSHOT
  • TABLE 102. COMPANY 6: OPERATING SEGMENTS
  • TABLE 103. COMPANY 6: PRODUCT PORTFOLIO
  • TABLE 104. COMPANY 6: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 105. COMPANY 7: KEY EXECUTIVES
  • TABLE 106. COMPANY 7: COMPANY SNAPSHOT
  • TABLE 107. COMPANY 7: OPERATING SEGMENTS
  • TABLE 108. COMPANY 7: PRODUCT PORTFOLIO
  • TABLE 109. COMPANY 7: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 110. COMPANY 8: KEY EXECUTIVES
  • TABLE 111. COMPANY 8: COMPANY SNAPSHOT
  • TABLE 112. COMPANY 8: OPERATING SEGMENTS
  • TABLE 113. COMPANY 8: PRODUCT PORTFOLIO
  • TABLE 114. COMPANY 8: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 115. COMPANY 9: KEY EXECUTIVES
  • TABLE 116. COMPANY 9: COMPANY SNAPSHOT
  • TABLE 117. COMPANY 9: OPERATING SEGMENTS
  • TABLE 118. COMPANY 9: PRODUCT PORTFOLIO
  • TABLE 119. COMPANY 9: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 120. COMPANY 10: KEY EXECUTIVES
  • TABLE 121. COMPANY 10: COMPANY SNAPSHOT
  • TABLE 122. COMPANY 10: OPERATING SEGMENTS
  • TABLE 123. COMPANY 10: PRODUCT PORTFOLIO
  • TABLE 124. COMPANY 10: KEY STRATEGIC MOVES AND DEVELOPMENTS

  • LIST OF FIGURES

  • FIGURE 1. GLOBAL ORGAN TRANSPLANT IMMUNOSUPPRESSANT DRUGS MARKET SEGMENTATION
  • FIGURE 2. GLOBAL ORGAN TRANSPLANT IMMUNOSUPPRESSANT DRUGS MARKET
  • FIGURE 3. SEGMENTATION ORGAN TRANSPLANT IMMUNOSUPPRESSANT DRUGS MARKET
  • FIGURE 4. TOP INVESTMENT POCKET IN ORGAN TRANSPLANT IMMUNOSUPPRESSANT DRUGS MARKET
  • FIGURE 5. MODERATE BARGAINING POWER OF BUYERS
  • FIGURE 6. MODERATE BARGAINING POWER OF SUPPLIERS
  • FIGURE 7. MODERATE THREAT OF NEW ENTRANTS
  • FIGURE 8. LOW THREAT OF SUBSTITUTION
  • FIGURE 9. HIGH COMPETITIVE RIVALRY
  • FIGURE 10. OPPORTUNITIES, RESTRAINTS AND DRIVERS: GLOBALORGAN TRANSPLANT IMMUNOSUPPRESSANT DRUGS MARKET
  • FIGURE 11. ORGAN TRANSPLANT IMMUNOSUPPRESSANT DRUGS MARKET SEGMENTATION, BY BY THERAPEUTICS
  • FIGURE 12. ORGAN TRANSPLANT IMMUNOSUPPRESSANT DRUGS MARKET FOR HEART TRANSPLANT, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 13. ORGAN TRANSPLANT IMMUNOSUPPRESSANT DRUGS MARKET FOR LUNG TRANSPLANT, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 14. ORGAN TRANSPLANT IMMUNOSUPPRESSANT DRUGS MARKET FOR KIDNEY TRANSPLANT, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 15. ORGAN TRANSPLANT IMMUNOSUPPRESSANT DRUGS MARKET FOR LIVER TRANSPLANT, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 16. ORGAN TRANSPLANT IMMUNOSUPPRESSANT DRUGS MARKET SEGMENTATION, BY BY COMMERCIALIZED PRODUCTS
  • FIGURE 17. ORGAN TRANSPLANT IMMUNOSUPPRESSANT DRUGS MARKET FOR ZENAPAX, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 18. ORGAN TRANSPLANT IMMUNOSUPPRESSANT DRUGS MARKET FOR PROGRAF, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 19. ORGAN TRANSPLANT IMMUNOSUPPRESSANT DRUGS MARKET FOR CELLCEPT, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 20. ORGAN TRANSPLANT IMMUNOSUPPRESSANT DRUGS MARKET FOR MYFORTIC, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 21. ORGAN TRANSPLANT IMMUNOSUPPRESSANT DRUGS MARKET FOR NEORAL, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 22. TOP WINNING STRATEGIES, BY YEAR, 2020-2022*
  • FIGURE 23. TOP WINNING STRATEGIES, BY DEVELOPMENT, 2020-2022*
  • FIGURE 24. TOP WINNING STRATEGIES, BY COMPANY, 2020-2022*
  • FIGURE 25. PRODUCT MAPPING OF TOP 10 PLAYERS
  • FIGURE 26. COMPETITIVE DASHBOARD
  • FIGURE 27. COMPETITIVE HEATMAP: ORGAN TRANSPLANT IMMUNOSUPPRESSANT DRUGS MARKET
  • FIGURE 28. Top player positioning, 2022
  • FIGURE 29. COMPANY 1: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 30. COMPANY 1: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 31. COMPANY 1: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 32. COMPANY 2: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 33. COMPANY 2: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 34. COMPANY 2: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 35. COMPANY 3: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 36. COMPANY 3: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 37. COMPANY 3: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 38. COMPANY 4: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 39. COMPANY 4: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 40. COMPANY 4: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 41. COMPANY 5: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 42. COMPANY 5: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 43. COMPANY 5: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 44. COMPANY 6: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 45. COMPANY 6: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 46. COMPANY 6: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 47. COMPANY 7: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 48. COMPANY 7: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 49. COMPANY 7: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 50. COMPANY 8: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 51. COMPANY 8: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 52. COMPANY 8: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 53. COMPANY 9: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 54. COMPANY 9: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 55. COMPANY 9: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 56. COMPANY 10: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 57. COMPANY 10: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 58. COMPANY 10: REVENUE SHARE, BY REGION, 2032 (%)

 
 
With collective industry experience of about 200 years of its analysts and experts, Allied Market Research (AMR) encompasses most infallible research methodology for its market intelligence and industry analysis. We do not only engrave the deepest levels of markets but also sneak through its slimmest details for the purpose of our market estimates and forecasts. Our approach helps in building greater market consensus view for size, shape and industry trends within each industry segment. We carefully factor in industry trends and real developments for identifying key growth factors and future course of the market. Our research proceeds are the resultant of high quality data, expert views and analysis and high value independent opinions. Our research process is designed to deliver balanced view of the global markets and allow stakeholders to make informed decisions.

We offer our clients exhaustive research and analysis based on wide variety of factual inputs, which largely include interviews with industry participants, reliable statistics and regional intelligence. Our in-house industry experts play instrumental role in designing analytic tools and models, tailored to the requirements of particular industry segment. These analytical tools and models sanitize the data & statistics and enhance the accuracy of our recommendations and advice. With AMR’s calibrated research process and 360` degree data-evaluation methodology, our clients are assured of receiving:

  • Consistent, valuable, robust and actionable data & analysis that can easily be referenced for strategic business planning
  • Technologically sophisticated and reliable insights through well audited and veracious research methodology
  • Sovereign research proceeds that present a tangible depiction of marketplace


With a strong methodology we are, therefore, confident that our research and analysis are most reliable and guarantees sound business planning.

Secondary research
We refer a broad array of industry sources for our secondary, which typically include; however, not limited to: Company SEC filings, annual reports, company websites, broker & financial reports and investor presentations for competitive scenario and shape of the industry

  • Patent and regulatory databases for understanding of technical & legal developments
  • Scientific and technical writings for product information and related preemptions
  • Regional government and statistical databases for macro analysis
  • Authentic new articles, web-casts and other related releases for market evaluation
  • Internal and external proprietary databases, key market indicators and relevant press releases for market estimates and forecast


Primary research
Our primary research efforts include reaching out participants through mail, tele-conversations, referrals, professional networks and face-to-face interactions. We are also in professional corporate relations with various companies that allow us greater flexibility for reaching out industry participants and commentators for interviews and discussions, fulfilling following functions:

  • Validates and improves the data quality and strengthens research proceeds
  • Further develops analyst team’s market understanding and expertise
  • Supplies authentic information about market size, share, growth and forecasts


Our primary research interview and discussion panels are typically composed of most experienced industry members. These participants include; however, not limited to:

  • Chief executives and VPs of leading corporations specific to industry
  • Product and sales managers or country heads; channel partners and top level distributors; banking, investments and valuation experts Key opinion leaders (KOLs)


Analyst tools and models
AMR has developed set of analyst tools and data models to supplement and expedite the analysis process. Corresponding to markets, where there is significant lack of information and estimates, AMR’s team of experts and analyst develop specific analyst tools and industry models to translate qualitative and quantitative industry indicators into exact industry estimates. These models also allow analysts to examine the prospects and opportunities prevailing in the market to accurately forecast the course of the market.

PURCHASE OPTIONS

Call or Email us

U.S.-Canada Toll-free: +1-800-792-5285
Int'l : +1-503-894-6022
Europe : +44-845-528-1300
Email : help@alliedmarketresearch.com

Looking for Customization?

 Customization Request

Have a Question?

 Speak with Analyst

Any Confusion?

 Inquire Before Buying

Have a glance of the Report

  Enquiry Now

Purchase Full Report of
Organ Transplant Immunosuppressant Drugs Market

Start reading.
This Report and over 66,804+ more Reports, Available with Avenue Library. T&C*.

  • Online Only
  • $3,690
  • Online cloud access only
  • Restricted print, copy, paste & download
  • Read only
  • Free industry update
    (Within 180 days)
  • Free report update in next update cycle
  • Data Pack
  • $3,930
  • Restricted to one authorized user
  • One print only
  • Available in
    Excel
  • Free industry update
    (Within 180 days)
  •   Free report update in next update cycle
  • Single User
  • $5,820
  • Restricted to one authorized user
  • One print only
  • Available in
    PDF
  • Free industry update
    (Within 180 days)
  •   Free report update in next update cycle
  • Five Users
  • $6,540
  • Limited to five authorized users
  • Print upto five copies
  • Available in
    PDF
  • Free industry update
    (Within 180 days)
  •   Free report update in next update cycle

  • Enterprise
    License/PDF

  • $9,870
  • Unlimited
    within
    company/enterprise
  • Available in Excel & PDF
  • Free industry update
    (Within 180 days)
  •   Free report update in next update cycle

  • Library
    Membership

  • $999 $ 1,175
    Per User/ Per month/ Billed annually
  • Published Content
    E-access
  • Company Profiles
    E-access
  • Newly Added Content Access
  • 10 PDF
    Downloads
  • 5 Excel Data
    Pack Downloads
  • 250 Company Profiles PDF Downloads
  • Buy Now

*Taxes/Fees, if applicable will be added during checkout. All prices in USD

RELATED REPORTS
 

Why Allied Market Research?

 

Infallible Methodology

To ensure high-level data integrity, accurate analysis, and impeccable forecasts

Analyst Support

For complete satisfaction

Customization

On-demand customization of scope of the report to exactly meet your needs

TARGETED MARKET VIEW

Targeted market view to provide pertinent information and save time of readers

Get fresh content delivered

Get insights on topics that are crucial for your business. Stay abreast of your interest areas.

Get Industry Data Alerts

Why Allied Market Research?

Infallible Methodology

To ensure high-level data integrity, accurate analysis, and impeccable forecasts

Analyst Support

For complete satisfaction

Customization

On-demand customization of scope of the report to exactly meet your needs

TARGETED MARKET VIEW

Targeted market view to provide pertinent information and save time of readers